BSECompany UpdateMgmt Change4 Sept 2026
Jenburkt Pharmaceuticals Ltd
Pursuant to Regulation 30 Read with Schedule III of the SEBI(Listing Obligations and Disclosure Requirnments ) Regulations 2015, we hereby inform you about the change in Senior Manaaement ....
Jenburkt Pharmaceuticals Ltd has announced the elevation of Shri. Prem Ashish Bhuta to Associate Vice President (AVP) – Strategic Initiatives, a senior management position, effective September 4, 2026. The appointment was made by the Board of Directors through a resolution passed by circulation.
BSECompany UpdateResults7 Aug 2026
Jenburkt Pharmaceuticals Ltd
Newspaper Publication for standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.
Jenburkt Pharmaceuticals Ltd has published its standalone unaudited financial results for the quarter ended on 30th June, 2026. The results are available on the company's website and the BSE website.
BSEResultResults6 Aug 2026
Jenburkt Pharmaceuticals Ltd
Standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.
Jenburkt Pharmaceuticals Ltd has announced its standalone unaudited financial results for the quarter ended on 30th June, 2026, with a profit before tax of Rs. 676.91 crores and a net profit of Rs. 588.56 crores.
BSEBoard MeetingResults6 Aug 2026
Jenburkt Pharmaceuticals Ltd
Outcome of the Board Meeting held today on 06th August, 2026.
Jenburkt Pharmaceuticals Ltd has announced its standalone unaudited financial results for the quarter ended 30 June 2026, with revenue from operations at Rs 3551.20 crore and profit after tax at Rs 588.56 crore.
BSECompany UpdateResults4 Aug 2026
Jenburkt Pharmaceuticals Ltd
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are enclosing herewith clippings of the Newspaper publication for Notice of the 41st AGM of the Company.
Jenburkt Pharmaceuticals Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on September 4, 2026, through video conferencing. The notice, along with the annual report for the financial year 2025-26, has been sent to members through electronic mode. Members will be able to cast their votes using the electronic voting system provided by National Securities Depository Limited (NSDL) from September 1 to 3, 2026.
BSEAGM/EGMResults3 Aug 2026
Jenburkt Pharmaceuticals Ltd
Notice of the 41st Annual General Meeting of the Company Schedule to be held on Friday, 04th September, 2026, through VC/OAVM.
Jenburkt Pharmaceuticals Ltd has announced the notice of its 41st Annual General Meeting (AGM) to be held on September 4, 2026, through video conferencing. The meeting will consider various resolutions, including the adoption of audited financial statements, dividend declaration, and reappointment of the Whole Time Director and CFO.
BSEOthersResults3 Aug 2026
Jenburkt Pharmaceuticals Ltd
Submission of the Annual Report for the FY 2025-26, containing Audited Standalone Financial Statements, Auditors Report and Directors Report and the Notice convening 41st Annual General ....
Jenburkt Pharmaceuticals Ltd has submitted its Annual Report for FY 2025-26, including audited standalone financial statements, auditors' report, and directors' report. The report also includes a notice convening the 41st Annual General Meeting to be held on September 4, 2026, and proposes to declare a dividend of ₹ 20.70 per equity share.
BSEBoard MeetingResults29 Jul 2026
Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve standalone unaudited ....
Jenburkt Pharmaceuticals Ltd has scheduled a Board Meeting on 06/08/2026 to consider and approve standalone unaudited financial results for the quarter ended 30/06/2026.